{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-023758","form_type":"8-K","ticker":"LTRN","cik":"0001763950","company_name":"Lantern Pharma Inc.","filed_at":"2026-05-15T20:07:33+00:00","discovered_at":"2026-05-15T20:13:00.225904+00:00","generated_at":"2026-05-15T20:13:27.986328+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lantern Pharma Q1 net loss down 27% YoY; FDA clears LP-300 trial amendments, IND for pediatric CNS cancer","bullets":["Net loss of $3.3M ($0.30/sh) vs $4.5M ($0.42/sh) in Q1 2025, a 27% reduction.","R&D expenses fell 47% YoY to $1.7M; cash & marketable securities $6.3M at March 31, plus $4.4M May financing.","Successful FDA Type C meeting for LP-300 HARMONIC trial; protocol amended to focus on EGFR exon 21 L858R mutation as single-arm study.","IND cleared for Starlight Therapeutics' STAR-001 pediatric CNS cancer trial (ATRT); Rare Pediatric Disease Designations.","Launched withZeta.ai commercial AI platform; announced plan to spin it into independent entity."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-023758","json":"https://secwatch.observer/filing/0001493152-26-023758.json","markdown":"https://secwatch.observer/filing/0001493152-26-023758.md","text":"https://secwatch.observer/filing/0001493152-26-023758.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226023758/0001493152-26-023758-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226023758/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T20:13:27.986328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6276c36aa7b13b84cdcc03cfedbb479e2ee5436f","claim":"Lantern Pharma Inc. reported financial results for the first quarter ended March 31, 2026.","evidence_excerpt":"On May 15, 2026, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the first quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226023758/0001493152-26-023758-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}